Status:
RECRUITING
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Use Disorder
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
This project aims to collect a densely sampled neuroimaging dataset among individuals receiving medications for opioid use disorder (MOUD). MOUD is multiphasic, comprised of medication induction, stab...
Detailed Description
MOUD individuals between the ages of 18 and 50 who recently enrolled in methadone treatment at APT Foundation clinics in the greater New Haven area. Investigators will aim to recruit individuals as ea...
Eligibility Criteria
Inclusion
- within the first 6 months of methadone treatment for OUD and on a stable dose of methadone
- eligibility for MRI scanning
- willing to commit to longitudinal study visits
Exclusion
- current psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5
- current co-occurring severe substance-use disorders (excluding nicotine and opioids), as assessed during screening with the SCID-5
- current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment (these individuals will be allowed to enroll at a later date once stable)
- severe cognitive impairment (determined through consent process conducted by trained clinical research staff and during consent quiz or as indicated by a PROMIS Cognitive Function t-score \<30 (i.e., score indicating severe impairment)
- Past or present history of intellectual disability or developmental disorder
- Neurological disease (including seizures or epilepsy) as assessed by self-report and by consulting clinic records
- Head trauma with loss of consciousness of more than 30 minutes
- Organ dysfunction or any unstable or untreated medical conditions that may alter cerebral function or interfere with study participation
Key Trial Info
Start Date :
October 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06207162
Start Date
October 10 2024
End Date
January 1 2026
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MRRC at The Anlyan Center
New Haven, Connecticut, United States, 06520